Test Your PBC Clinical Decision Knowledge
Reviewed by: HU Medical Review Board | Last reviewed: June 2026 | Last updated: July 2026
Primary biliary cholangitis (PBC) management encompasses serologic and biochemical diagnosis, risk-stratified treatment decisions, and long-term surveillance. The following 5 questions span that territory – diagnostic criteria, biochemical response assessment, the current second-line landscape, symptom management, and cirrhosis surveillance. Each is grounded in society guidance and peer-reviewed evidence to help you benchmark your clinical decision-making.
Clinical Challenge
In a patient with cholestatic liver biochemistries, which combination supports a diagnosis of primary biliary cholangitis (PBC) without a liver biopsy?
Clinical Challenge
A patient with PBC has completed 12 months of ursodeoxycholic acid (UDCA) at 13 to 15 mg/kg/day, with a persistently elevated ALP at 2.5 times the upper limit of normal (ULN). How is this best characterized?
Clinical Challenge
For a patient with an inadequate response to UDCA, which describes the currently available add-on pharmacologic options?
Clinical Challenge
Which statement about cholestatic pruritus in PBC is correct?
Clinical Challenge
A patient with PBC and established cirrhosis is otherwise stable on therapy. Which surveillance is indicated?